Full-Time

Director – Market Access and Channel Strategy

Confirmed live in the last 24 hours

Takeda

Takeda

10,001+ employees

Develops and commercializes biopharmaceuticals and vaccines

Compensation Overview

$174.5k - $274.2k/yr

+ Short-term Incentives + Long-term Incentives

Senior, Expert

Boston, MA, USA

This position is classified as 'hybrid' in accordance with Takeda's Hybrid and Remote Work policy, indicating a mix of remote and in-office work.

Category
Strategy Development
Business Development
Business & Strategy
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a Takeda referral from your network.

💡

Applications through a referral are 3x more likely to get an interview!

Requirements
  • Bachelor’s degree in related field required; MBA, PharmD, or MS in health sciences related field highly preferred
  • 10+ years of experience in biopharma required; biopharma market access experience highly preferred
  • Understanding of U.S. payer market dynamics and how managed care organizations make decisions across commercial and public channels
  • Channel knowledge across payer, PBM, IDN, GPO, specialty pharmacy, etc.
  • Knowledge of specialty pharmacy (how they operate, drivers, strengths, etc.) to ensure a positive patient experience
  • Broad knowledge across multiple therapeutic areas and disease states required; knowledge of specialty products preferred
  • Knowledge of the commercial brand planning processes
  • Experience working across Medical, Legal, Finance, Analytics, Public Affairs, etc.
  • Financial acumen including resource allocation, budget management and reporting, strategic sourcing, and P&L evaluation
  • Analytical capabilities to ensure robust inputs to decision-making
  • Travel ~10% (domestic)
Responsibilities
  • Identify, develop, and recommend portfolio-level strategies and opportunities across access levers and work across the USBU to successfully implement and monitor chosen solutions
  • Partner with members of Market Access and Channel Strategy on pipeline and inline product strategy to determine portfolio considerations and opportunities and evaluate how franchise and brand-specific actions impact the broader USBU
  • Monitor and evaluate evolving regulatory and industry dynamics (e.g., pricing reform) to ensure proactive and leading market access and channel strategies
  • Consider the current and future landscape when evaluating and recommending solutions by keeping a pulse on developing competitor and market access trends (e.g., formulary narrowing, pharmacy reimbursement, major stakeholder company strategies, etc.)
  • Provide support and collaboration to cross-functional PAMA teams on enterprise priorities to ensure Takeda’s long-term success by translating enterprise work into innovative and portfolio/brand-specific strategies
  • Oversee internal and external operations, including pricing and contracting philosophy, business case team alignment, deliverable standardization, and consultant and agency selection and oversight
  • Develop and oversee sustainable market access and channel strategies that will allow patients to gain access to Takeda’s existing and future products
  • Responsible for value story development, contracting strategy, pricing, specialty pharmacy and distribution plans, reimbursement, and marketing resources
  • Ensure close collaboration with other Managed Markets and Patient Access colleagues along with Medical, Health Economics and Outcomes Research (HEOR), Marketing, Finance, Analytics, and Sales to capture relevant payer and channel insights, identify data gaps, develop compelling value propositions, and ensure field-based teams are equipped with the right tools
  • Understand the reimbursement landscape and incorporate knowledge into market access and pricing strategy
  • Collaborate with HEOR in the development of payer evidence needs and ensure it is integrated into the Medical/HEOR evidence plan
  • Align within the organization on metrics to assess impacts of key market access strategies and tactics
  • Manage and execute payer and channel specific marketing plans to achieve patient and business objectives
  • Contribute to the annual brand planning, forecasting, and budgeting process to represent payer and channel customer segments and ensures brand plans incorporate the needs of patients, payers, and healthcare providers
  • Partner with New Product Planning and Business Development functions to inform market access inputs and strategies for early stage/targeted assets
  • Identify, as appropriate, opportunities for innovative arrangements based on portfolio, franchise, and brand strategies in collaboration with other functional areas
Desired Qualifications
  • biopharma market access experience highly preferred
  • MBA, PharmD, or MS in health sciences related field highly preferred
  • knowledge of specialty products preferred

Takeda Pharmaceutical Company Limited is a global biopharmaceutical firm that focuses on developing and delivering treatments and vaccines for patients. The company invests heavily in research and development to create new molecular entities (NMEs) and has a pipeline of 11 NMEs, aiming for up to 15 product launches by FY2024. Takeda's products are designed to meet the needs of healthcare providers, hospitals, and patients around the world. What sets Takeda apart from its competitors is its strong commitment to patient-centric values and environmental sustainability, recognizing the connection between human health and environmental health. The company's goal is to innovate and provide life-changing therapies while ensuring that patient needs are prioritized in all operations.

Company Size

10,001+

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1781

Simplify Jobs

Simplify's Take

What believers are saying

  • Takeda's focus on personalized medicine can increase treatment efficacy and patient satisfaction.
  • Expansion in Southeast Asia offers opportunities for increased market presence and revenue growth.
  • Collaborations with tech companies can accelerate R&D processes and reduce costs.

What critics are saying

  • Data breach could lead to financial and reputational damage for Takeda.
  • Antitrust litigation with Meijer may result in financial penalties or business practice changes.
  • High financial commitments in partnerships could strain resources if outcomes are not achieved.

What makes Takeda unique

  • Takeda has a 240-year history in the biopharmaceutical industry.
  • The company emphasizes patient-centric values in its operations and R&D efforts.
  • Takeda's robust pipeline includes 11 NMEs with plans for 15 product launches by FY2024.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Wellness Program

Tuition Reimbursement

Company News

CyberNews
Apr 15th, 2025
Hackers want $75,000 for data allegedly stolen from Takeda

A new account on an illicit forum bearing the moniker "beltway" claims that in April 2025, it exported around two million rows of user information from Takeda.com.

MLex
Mar 4th, 2025
Meijer seeks quick appeal in US antitrust case against Takeda

( March 4, 2025, 17:06 GMT | Official Statement) - MLex Summary: Meijer asked a US federal judge for leave to immediately appeal an order that sent its antitrust case against Takeda Pharmaceuticals over the drug Amitiza to arbitration.

BioSpace
Mar 3rd, 2025
Takeda-Protagonist Drug for Incurable Cancer Reduces Need for Blood Withdrawals in Phase III Trial

Protagonist, which will receive a $25 million milestone from Takeda thanks to the positive results, plans to submit the findings to regulators.

Access Health
Mar 3rd, 2025
Strengthening Access to Medicines in Southeast Asia: Highlights from Southeast Asia Access to Medicine (SEA AtM) Summit

ACCESS Health International, in collaboration with AVPN, SingHealth Duke-NUS Global Health Institute, and Takeda, successfully co-hosted the first Southeast Asia Access to Medicine (SEA AtM) Summit in Bangkok.

Pharmaceutical Technology
Feb 25th, 2025
Takeda broadens its deal with BridGene for up to $770m

Bridgene and Takeda have inked a deal worth $770m to develop small molecules for immunology and neurology.